Form 4 for ARQT Arcutis Biotherapeutics, Inc.

Accepted 2025-02-04 00:00:00 ET · period of report 2025-02-03 · accession 0001787306-25-000017 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
	2025-02-04	2025-02-03	ARQT	Matsuda Masaru	See Remarks	S - Sale	$12.70	-8,338	178.7K	-4%	-$105.9K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2025-02-03	S	D	8,338	$12.70	178,692	D	—	—	(F1) The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs"), granted on January 12, 2024, in which 25% of the RSUs vest annually on February 1, (the "Vesting Commencement Date"), of each year beginning on February 1, 2025, subject to the Reporting Person's continued service to the Issuer. (F2) The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $12.545 to $13.0096, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. (F3) Reflects the adjusted total which includes the acquisition of 4,000 shares and 1,657 shares under the Company's Employee Stock Purchase Plan on May 31, 2024 and November 30, 2024, respectively, which transactions were exempt from Section 16(a) and (b) and were erroneously reported as non-exempt purchases in the Reporting Person's Form 4 filed on December 3, 2024.